Question:
Are there any new pass-through drugs for the upcoming quarter?
Answer:
The Centers for Medicare & Medicaid Services (CMS) have granted outpatient prospective payment system (OPPS) pass-through status, effective July 1, 2018 the following drugs and biological:
C9030 | Injection, copanlisib, 1 mg |
C9031 | Lutetium Lu 177, dotatate, therapeutic, 1 mCi |
C9032 | Injection, voretigene neparvovec-rzyl, 1 billion vector genome |
Q9991 | Injection, buprenorphine extendedrelease (Sublocade), less than or equal to 100 mg |
Q9992 | Injection, buprenorphine extendedrelease (Sublocade), greater than 100 mg |
Q9995 | Injection, emicizumab-kxwh, 0.5 mg |